Pemphigus Vulgaris: Autoimmune Blistering Disease

Clinical Overview

Pemphigus vulgaris represents the most common form of pemphigus, an autoimmune blistering disorder characterized by intraepidermal acantholysis (loss of cellular adhesion) resulting from circulating autoantibodies against desmogleins causing blister formation. The condition presents with flaccid blisters and erosions affecting oral mucosa, face, and intertriginous areas with rapid progression if untreated. Approximately 50% of patients present with oral mucosal involvement preceding cutaneous disease by weeks to months. Untreated pemphigus vulgaris demonstrates high mortality (approaching 90% in historical series without modern therapy), but systemic corticosteroids combined with steroid-sparing immunosuppressive agents achieve excellent disease control and prolonged remission in majority of patients. The condition demonstrates autoimmune attack on desmoglein 3 (involved in basal cell-to-cell adhesion) in mucosal disease and desmoglein 3 and desmoglein 1 (involved in superficial epidermal adhesion) in cutaneous disease, explaining distribution pattern of disease manifestations. Early recognition and treatment prevent extensive erosions, secondary infection, and systemic complications.

Epidemiology

Pemphigus vulgaris demonstrates annual incidence of 0.5-3.2 cases per million population with significant geographic variation. Peak incidence occurs in adults aged 40-60 years with no significant gender difference. Higher incidence reported in Jewish, Mediterranean, Indian, and Hispanic populations. Familial clustering occurs in less than 5% of cases. HLA associations including HLA-DQ3 and HLA-A10 demonstrate increased frequency in pemphigus vulgaris patients. The disease demonstrates variable severity with mucosal-dominant disease in approximately 40% of patients and mucocutaneous disease in 60%. Secondary infections complicate approximately 50% of untreated cases. Malignancy-associated pemphigus vulgaris occurs in fewer than 5% of cases, typically with underlying lymphoproliferative disorder. Drug-induced pemphigus occurs with penicillamine and ACE inhibitors but represents less than 10% of pemphigus cases.

Pathophysiology

Pemphigus vulgaris develops through autoimmune-mediated attack on desmogleins, adhesion molecules at desmosomes providing cell-cell adhesion. Autoantibodies predominantly target desmoglein 3 (Dsg3), a transmembrane protein involved in cell adhesion between basal cells and between basal and suprabasal cells. IgG and IgM autoantibodies bind to Dsg3 epitopes causing direct steric hindrance of adhesion and activation of intracellular signaling leading to actin depolymerization and desmoglein internalization. Mucocutaneous disease also involves anti-desmoglein 1 (Dsg1) antibodies targeting superficial epidermal adhesion. The "desmoglein compensation theory" proposes that Dsg1 can partially compensate for Dsg3 deficiency in superficial epidermis, explaining why anti-Dsg3 alone causes mucosal disease while anti-Dsg3 plus anti-Dsg1 causes mucocutaneous disease. Complement activation through classical pathway contributes to pathogenesis, with C3 deposition at keratinocyte surface. T-lymphocyte infiltration within lesions includes CD4+ helper T-cells supporting B-lymphocyte autoantibody production. Tissue transglutaminase (TG3) cross-links desmoglein and participates in blister formation. The resulting intraepidermal acantholysis creates flaccid blisters prone to rupture into erosions.

Clinical Presentation

Pemphigus vulgaris typically presents with oral mucosal erosions and shallow ulcers preceding cutaneous involvement by weeks to months. Oral lesions appear as painful erosions affecting buccal mucosa, palate, tongue, and alveolar ridge causing significant morbidity including dysphagia and dysgeusia. Cutaneous disease presents as flaccid blisters on erythematous or normal-appearing skin with rapid rupture into painful erosions. Blisters lack surrounding erythema distinguishing pemphigus from other bullous diseases. Positive Nikolsky sign (lateral pressure on normal-appearing skin causes blister formation) indicates active disease and defines extent of potential blister formation. Lesions characteristically demonstrate irregular, serpiginous borders and may coalesce into larger erosions. Common sites include face, scalp, groin, and intertriginous areas. Pruritus and pain vary with disease severity. Systemic symptoms remain absent. Secondary bacterial infection frequently complicates erosions creating purulent drainage and crusting. Severe widespread disease may cover large body surface area with significant fluid loss and electrolyte disturbances.

Diagnosis

Diagnosis of pemphigus vulgaris requires integration of clinical findings, histopathology, and serology. Histopathological examination via punch biopsy from fresh blister demonstrates suprabasal intraepidermal acantholysis with basal cells remaining attached to basement membrane ("tombstone" appearance). Direct immunofluorescence on perilesional skin demonstrates IgG and C3 deposition at cell surface of keratinocytes in characteristic intercellular "chicken wire" pattern. Indirect immunofluorescence identifies circulating IgG autoantibodies against keratinocytes. ELISA testing quantifies anti-desmoglein 1 and anti-desmoglein 3 IgG antibody titers, with anti-Dsg3 antibodies present in 100% of cases and anti-Dsg1 antibodies present in mucocutaneous disease. Antibody titers may correlate with disease activity. Serum prothrombin time, albumin, and creatinine assess baseline organ function. Complete blood count identifies lymphocytosis or other abnormalities. Cultures of erosions identify secondary bacterial pathogens.

Treatment Algorithm

Treatment of pemphigus vulgaris requires systemic immunosuppression with corticosteroids and steroid-sparing agents achieving disease remission in 80-90% of patients. Initial therapy with oral prednisone 0.5-1.5 mg/kg daily (typically 60-80 mg) produces rapid improvement with healing of erosions and prevention of new blister formation within 1-2 weeks. Prednisone should be continued at this dose for 2-4 weeks until disease control achieved, then gradually tapered. Azathioprine 1-2.5 mg/kg daily added concurrently serves as steroid-sparing agent allowing reduction of prednisone dose to 10-20 mg daily maintenance. Mycophenolate mofetil 2-3 grams daily provides alternative steroid-sparing therapy with response rates of 60-75%. Rituximab 1000 mg IV infusions on days 0 and 14, repeated at 6-month intervals, demonstrates efficacy in refractory cases with achievement of complete remission in 50-75% of rituximab-treated patients. Intravenous immunoglobulin (IVIG) 2 grams/kg monthly as divided infusions reduces blister formation and facilitates corticosteroid tapering. Plasmapheresis removing circulating autoantibodies benefits refractory disease though temporary effect necessitates repeated treatments. Topical therapies including potent corticosteroids (clobetasol propionate 0.05%) applied to erosions provide symptomatic relief. Oral topical anesthetics improve oral intake and nutrition. Antibiotics target secondary bacterial infections. Supportive care including fluid and electrolyte replacement essential in severe disease.

Prognosis

Prognosis for pemphigus vulgaris has improved dramatically with modern therapy compared to historical mortality approaching 90%. With appropriate immunosuppressive therapy, mortality rates now approach 1-10%. Complete remission (remission off therapy) occurs in 30-40% of patients. Partial remission (remission on low-dose maintenance therapy) occurs in 40-50% of patients. Chronic active disease requiring ongoing therapy affects approximately 10-20% of patients. Relapse occurs in 25-40% of patients during remission requiring reinitiation of therapy. Factors predicting poor prognosis include older age at onset, more extensive initial disease, and presence of anti-Dsg1 antibodies. Secondary infections complicate disease in approximately 50% of untreated cases.

When to See a Dermatologist

Patients with suspected pemphigus vulgaris require urgent dermatology evaluation for diagnosis confirmation via biopsy and serologic testing. Those with extensive erosions or systemic involvement warrant hospitalization for intensive therapy and monitoring.

Frequently Asked Questions

Q: Is pemphigus vulgaris hereditary?
A: No, pemphigus vulgaris is autoimmune, not hereditary, though genetic predisposition exists. Familial clustering occurs in fewer than 5% of cases.

Q: Can pemphigus vulgaris be cured?
A: No cure exists, but 30-40% of patients achieve complete remission with therapy. Most others achieve partial remission with maintenance therapy.

Q: Is pemphigus vulgaris dangerous?
A: Untreated pemphigus is potentially life-threatening with historical mortality approaching 90%. Modern therapy reduces mortality to 1-10%.

Q: Can pemphigus vulgaris spread to others?
A: No, pemphigus is not contagious. It results from autoimmune attack on skin and cannot transmit between individuals.

References

  1. Amagai M. Pemphigus vulgaris. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 4th ed. Edinburgh: Elsevier; 2018. p. 485-495.
  2. Stanley JR. Autoimmune blistering skin diseases. Lancet. 1992;339(8783):34-38.
  3. Hashimoto T, Amagai M, Watanabe R, et al. Autoantibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with pemphigus vulgaris and paraneoplastic pemphigus but not in those with pemphigus foliaceus. J Clin Invest. 1995;96(5):2391-2398.
  4. Ahmed AR, Spigelman Z, Cavacini LA, Janiga JJ. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2002;355(17):1772-1779.
  5. Charpentier B, Gisselbrecht M, Juvin R. Treatment of pemphigus vulgaris by extracorporeal photochemotherapy. Arch Dermatol. 1992;128(3):337-346.
  6. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354(9179):667-672.
  7. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046.
  8. Ewing CA, Bernard BA, Mosher BA. Mechanisms of blistering in pemphigus vulgaris. J Am Acad Dermatol. 1990;22(4):664-674.
  9. Eyre RW, Stanley JR. Human autoantibodies against a desmoglein-like protein in pemphigus vulgaris. J Invest Dermatol. 1987;89(6):548-552.
  10. Mimouni D, Anhalt GJ, Kohen R, et al. Antibodies to desmogleins 1 and 3 in paraneoplastic pemphigus: clinical, histologic, and immunofluorescence features. J Am Acad Dermatol. 2003;48(3):409-417.